Distinguished Cancer Drug Developer Joins Samaritan Scientific Advisory Board
01 Mars 2006 - 2:00PM
Business Wire
Samaritan Pharmaceuticals, Inc. (AMEX:LIV), a developer of
innovative drugs, announced today the welcoming of Dr. Pauline S.
Nys, a distinguished leader and innovator in the field of
anticancer and cardiovascular drug development, to its Scientific
Advisory board. Dr. Nys was a Full Professor of Biotechnology at
the Research Center for Antibiotics, in Moscow, Russia. Presently,
she serves as a Scientific Advisor to a few European and US
biotechnological companies. Dr. Nys has published more than 100
articles in international scientific journals, as well as
presenting numerous professional papers at scientific meetings. In
addition, she is the author of more than 25 patents for
biologically active compound production. Dr. Greeson, CEO of
Samaritan, stated, "We are delighted to be able to rely on Dr. Nys'
expertise in Cancer and Cardiovascular drug development; she really
is a remarkable woman." Samaritan Pharmaceuticals: "We LIV....to
Save Lives." Samaritan is a small-cap Biotech, driven to discover,
develop, and commercialize innovative therapeutics for AIDS,
Alzheimer's, Cancer and Heart disease. Look at
www.samaritanpharma.com.
Emles at Home ETF (AMEX:LIV)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Emles at Home ETF (AMEX:LIV)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Emles at Home ETF (American Stock Exchange): 0 recent articles
Plus d'articles sur Samaritan Pharmaceuticals Inc.